Refine
Document Type
- Article (4)
- Preprint (4)
- diplomthesis (1)
- Doctoral Thesis (1)
Has Fulltext
- yes (10)
Is part of the Bibliography
- no (10)
Keywords
- Blei-Reaktion (1)
- Bleitarget (1)
- Hyperon (1)
- Pharmacodynamics (1)
- Target validation (1)
- Ultrarelativistischer Bereich (1)
Institute
The bile acid activated transcription factor farnesoid X receptor (FXR) regulates numerous metabolic processes and is a rising target for the treatment of hepatic and metabolic disorders. FXR agonists have revealed efficacy in treating non-alcoholic steatohepatitis (NASH), diabetes and dyslipidemia. Here we characterize imatinib as first-in-class allosteric FXR modulator and report the development of an optimized descendant that markedly promotes agonist induced FXR activation in a reporter gene assay and FXR target gene expression in HepG2 cells. Differential effects of imatinib on agonist-induced bile salt export protein and small heterodimer partner expression suggest that allosteric FXR modulation could open a new avenue to gene-selective FXR modulators.